The plummeting cost of genome sequencing may likely spur a jump in healthcare spending, Forbes contributor Peter Ubel says, and he thinks that maybe something ought to be done about that.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

To Tell?

The Pair of Them

Human Knockouts

Following the Curve

Not Yet Sure

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."